Patents by Inventor Ye Edward Tian

Ye Edward Tian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Immunoglobulin Fusion Proteins and Methods of Making
    Publication number: 20110110945
    Abstract: Disclosed are immunoglobulin fusion proteins and methods of making such proteins. In certain embodiments, the fusion protein may include a non-immunoglobulin polypeptide linked to an immunoglobulin polypeptide. In certain embodiments, the non-immunoglobulin polypeptide may comprise a region that replaces an immunoglobulin Fc hinge region, but that allows for correct assembly of the immunoglobulin chains.
    Type: Application
    Filed: October 6, 2010
    Publication date: May 12, 2011
    Applicant: TransTech Pharma, Inc.
    Inventors: Adnan M.M. Mjalli, Ye Edward Tian, Jeffrey C. Webster, Robert Rothlein
  • Rage fusion proteins
    Patent number: 7901688
    Abstract: Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to an immunoglobulin CH2 domain. Such fusion proteins may provide specific, high affinity binding to RAGE ligands. Also disclosed is the use of the RAGE fusion proteins as therapeutics for RAGE-mediated pathologies.
    Type: Grant
    Filed: August 3, 2005
    Date of Patent: March 8, 2011
    Assignee: Transtech Pharma, Inc.
    Inventors: Adnan M. M. Mjalli, Ye Edward Tian, Jeffrey C. Webster, Robert Rothlein
  • Rage Fusion Proteins and Methods of Use
    Publication number: 20090060925
    Abstract: Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to an immunoglobulin CH2 domain. Such fusion proteins may provide specific, high affinity binding to RAGE ligands. Also disclosed is the use of the RAGE fusion proteins as therapeutics for RAGE-mediated pathologies.
    Type: Application
    Filed: August 3, 2005
    Publication date: March 5, 2009
    Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF
    Inventors: Adnan M.M. Mjalli, Ye Edward Tian, Jeffrey C. Webster, Robert Rothlein, David M. Stern, Ann Marie Schmidt, Shi Du Yan
  • Immunoglobulin fusion proteins and methods of making
    Publication number: 20080199467
    Abstract: Disclosed are immunoglobulin fusion proteins and methods of making such proteins. In certain embodiments, the fusion protein may include a non-immunoglobulin polypeptide linked to an immunoglobulin polypeptide. In certain embodiments, the non-immunoglobulin polypeptide may comprise a region that replaces an immunoglobulin Fc hinge region, but that allows for correct assembly of the immunoglobulin chains.
    Type: Application
    Filed: February 11, 2008
    Publication date: August 21, 2008
    Inventors: Adnan M. M. Mjalli, Ye Edward Tian, Jeffrey C. Webster, Robert Rothlein
  • VEGF responsive cell-based assay for determining VEGF bioactivity
    Patent number: 6787323
    Abstract: A VEGF responsive cell-based assay for determining VEGF bioactivity is disclosed. The assay utilizes established signal transduction pathways in a method for determining VEGF bioactivity in a sample.
    Type: Grant
    Filed: February 7, 2002
    Date of Patent: September 7, 2004
    Assignee: Pfizer Inc
    Inventors: Brian Lee Batley, Tawny Kay Dahring, Sotirios K. Karathanasis, Robert Lee Panek, Ye Edward Tian
  • VEGF responsive cell-based assay for determining VEGF bioactivity
    Publication number: 20020110830
    Abstract: A VEGF responsive cell-based assay for determining VEGF bioactivity is disclosed. The assay utilizes established signal transduction pathways in a method for determining VEGF bioactivity in a sample.
    Type: Application
    Filed: February 7, 2002
    Publication date: August 15, 2002
    Inventors: Brian Lee Batley, Tawny Kay Dahring, Sotirios K. Karathanasis, Robert Lee Panek, Ye Edward Tian